NKTR Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 10.24%. Nektar Therapeutics's return on equity of -327.67% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Nektar Therapeutics has a consensus price target of $107.29, signalling upside risk potential of 85.97%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.90 which suggests that it could grow by 59.8%. Given that Nektar Therapeutics has higher upside potential than Amicus Therapeutics, Inc., analysts believe Nektar Therapeutics is more attractive than Amicus Therapeutics, Inc..

Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Nektar Therapeutics's net income of -$35.5M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 59.49x versus 5.09x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 31.72%. Nektar Therapeutics's return on equity of -327.67% beat Eli Lilly & Co.'s return on equity of 106.26%.

Nektar Therapeutics has a consensus price target of $107.29, signalling upside risk potential of 85.97%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.16%. Given that Nektar Therapeutics has higher upside potential than Eli Lilly & Co., analysts believe Nektar Therapeutics is more attractive than Eli Lilly & Co..

Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Nektar Therapeutics's net income of -$35.5M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 59.49x versus 15.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 38.89%. Nektar Therapeutics's return on equity of -327.67% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Nektar Therapeutics has a consensus price target of $107.29, signalling upside risk potential of 85.97%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.07%. Given that Nektar Therapeutics has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Regeneron Pharmaceuticals, Inc..

Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Nektar Therapeutics's net income of -$35.5M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 59.49x versus 5.59x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of -2.09%. Nektar Therapeutics's return on equity of -327.67% beat Zevra Therapeutics, Inc.'s return on equity of 44.06%.

Nektar Therapeutics has a consensus price target of $107.29, signalling upside risk potential of 85.97%. On the other hand Zevra Therapeutics, Inc. has an analysts' consensus of $23.10 which suggests that it could grow by 158.52%. Given that Zevra Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Zevra Therapeutics, Inc. is more attractive than Nektar Therapeutics.

Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Zevra Therapeutics, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.92699999999999%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Zevra Therapeutics, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Zevra Therapeutics, Inc. quarterly revenues of $26.1M. Nektar Therapeutics's net income of -$35.5M is lower than Zevra Therapeutics, Inc.'s net income of -$544K. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Zevra Therapeutics, Inc.'s PE ratio is 13.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 59.49x versus 5.64x for Zevra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.